Home › Funds › PFM Health Sciences, LP › AMRX
PFM Health Sciences, LP position in AMRX
AMNEAL PHARMACEUTICALS INC · Health Care
PFM Health Sciences, LP reported holding 480,715 shares of AMRX (AMNEAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$8.3M, representing 0.73% of its reported portfolio and ranking #48 among its reported holdings. PFM Health Sciences, LP has disclosed AMRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How PFM Health Sciences, LP's AMRX position evolved
PFM Health Sciences, LP first disclosed a stake in AMRX in Q3 2025 at 355,818 shares (US$3.6M). The position peaked in Q4 2025 at 1,465,480 shares, worth US$18.5M. Across 4 filings, PFM Health Sciences, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 480,715 shares valued at US$8.3M — a reduction of -449,381 shares quarter over quarter.. Notable position changes include a 312% increase in Q4 2025 (shares fell 1% over the following quarter), a 37% trim in Q1 2026 (shares rose 39% over the following quarter), a 48% trim in Q2 2026 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 355.82K | $3.56M | New |
| Q4 2025 | 1.47M | $18.47M | Add |
| Q1 2026 | 930.10K | $11.56M | Reduce |
| Q2 2026 | 480.71K | $8.32M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMRX and 13F data
AMRX (AMNEAL PHARMACEUTICALS INC) is a Health Care company. 48 other funds we track also report a position in AMRX — the largest reported positions include TPG GP A, LLC (US$213.4M), Rubric Capital Management LP (US$176.0M), Nantahala Capital Management, LLC (US$39.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMRX
- TPG GP A, LLC 12.33M sh · $213.41M · Q2 2026
- Rubric Capital Management LP 10.17M sh · $176.02M · Q2 2026
- Nantahala Capital Management, LLC 2.27M sh · $39.27M · Q2 2026
- Westshore Wealth, LLC 1.37M sh · $23.65M · Q2 2026
- BlackBarn Capital Partners LP 1.30M sh · $22.50M · Q2 2026
- Penn Capital Management Company, LLC 1.18M sh · $20.48M · Q2 2026
- TUCKER ASSET MANAGEMENT LLC 1.01M sh · $17.50M · Q2 2026
- Phocas Financial Corp. 819.48K sh · $14.19M · Q2 2026
More on PFM Health Sciences, LP
FAQ
How long has PFM Health Sciences, LP held AMRX?
PFM Health Sciences, LP has disclosed AMRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is PFM Health Sciences, LP's current position in AMRX?
As of Q2 2026, PFM Health Sciences, LP holds 480.71K shares of AMRX (AMNEAL PHARMACEUTICALS INC), valued at $8.32M, representing 0.73% of its reported portfolio and ranking #48.
Has PFM Health Sciences, LP been buying or selling AMRX?
In the latest 13F filing (Q2 2026), PFM Health Sciences, LP reduced its position in AMRX. The position peaked in Q4 2025 at 1.47M shares.
Which other funds hold AMRX?
Other major institutional holders of AMRX include TPG GP A, LLC, Rubric Capital Management LP, Nantahala Capital Management, LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.